Skip to main content

Anti-Rheumatic Rx

      By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
      RT @Janetbirdope: Some / most of promises of #JAKi are fulfilled. Efficacy, adherence = on mono vs combination Rx with M

      Janet Pope Janetbirdope

      3 years 4 months ago
      Some / most of promises of #JAKi are fulfilled. Efficacy, adherence = on mono vs combination Rx with MTX. But some emerging safety issues. NK cells reduce inflammation of NK cells on fibroblasts re other MOA. @eular #EULAR2022 ⁦@RheumNow⁩ The promise of #JAKi I RA https://t.co/8Ry3vVMyzO
      RT @ericdeinmd: #EULAR2022 POS0213
      Beware of paradoxical low lipids in RA!
      ⭐️ETN+MTX vs MTX T2T:
      Early ETN: increase

      Eric Dein ericdeinmd

      3 years 4 months ago
      #EULAR2022 POS0213 Beware of paradoxical low lipids in RA! ⭐️ETN+MTX vs MTX T2T: Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity @RheumNow https://t.co/c6GXadVwYN
      Update in Spondyloarthritis
      A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
      EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye because they can potentially impact medical practice.
      RT @doctorRBC: Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in di

      Robert B Chao, MD doctorRBC

      3 years 4 months ago
      Methotrexate plus leflunomide combination therapy for PsA treatment resulted in greater improvement in disease activity when compared to MTX monotherapy. As expected, MTX+LEF less well tolerated. @RheumNow #EULAR2022 ABST#0078 https://t.co/Bo64QX3Bf9
      RT @doctorRBC: Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to eta

      Robert B Chao, MD doctorRBC

      3 years 4 months ago
      Study of 2.9k offspring exposed to adalimumab, infliximab, golimumab during pregnancy, as compared to etanercept and certolizumab showed an adjusted hazard ratio for serious infections of 1.20 (CI 0.54, 2.64). @RheumNow #EULAR2022 ABST#OP0130
      Golden Window in Pre-RA
      RT @doctorRBC: No significant difference in malignancy risk in patients with rheumatic disease and a prior history of ma

      Robert B Chao, MD doctorRBC

      3 years 4 months ago
      No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
      RT @AurelieRheumo: Does MTX have an impact on UST-immunogenicity in PsA?

      Post-hoc analysis from UST RCT in 110+ pts

      No

      Aurelie Najm AurelieRheumo

      3 years 4 months ago
      Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
      ×